Agenus data at ctos 2022 highlight durable clinical responses of botensilimab / balstilimab combination in advanced sarcoma

Lexington, mass., nov. 17, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the company's phase 1 study of botensilimab (fc-enhanced anti-ctla-4) and balstilimab (anti-pd-1) in patients with advanced sarcoma. the data demonstrate that the combination offers strong durability and superior efficacy compared to what has been reported in separate trials for standard of care and other investigational therapies in sarcoma, including in sarcoma subtypes historically unresponsive to immunotherapy. the results will be presented tomorrow in an oral presentation at the connective tissue oncology society (ctos) 2022 annual meeting in vancouver, bc, canada.
AGEN Ratings Summary
AGEN Quant Ranking